Skip to main content
Grafa
Biogen wins FDA approval for high-dose SPINRAZA regimen in spinal muscular atrophy
Image for illustrative purposes only. Not a real photo.

Biogen wins FDA approval for high-dose SPINRAZA regimen in spinal muscular atrophy

Share

Biogen (NASDAQ:BIIB) said the FDA approved a higher-dose regimen of its SPINRAZA (nusinersen) therapy for patients with spinal muscular atrophy (SMA).

More ways to discover

Browse United States newsDiscover NYSE signalsBrowse all NYSE stocksBrowse all NYSE ETFsExplore United States companiesFind the right NYSE index